Drug Design Development and Therapy · 2016 · 41 citations · 13 references
MedicineOncologyPharmacologyApoptosisCancer PharmacologyMolecular OncologyApoptosis In CancerApoptosis RegulationCell-cycle DysregulationCyclin-dependent KinasesTargeted Cancer TherapyAnticancer ActivityBcl-2 Protein ExpressionCdk InhibitorsCyclin D RegulationCyclin RegulationCyclin-dependent Kinase InhibitorsTherapeutic Cyclin-dependent Kinase InhibitionTherapeutic Target Identification
Cyclin-dependent kinase (CDK) family members have been considered as attractive therapeutic targets for cancer. In this study, we aim to investigate the anticancer effects of a selective CDK7 inhibitor, BS-181, in gastric cancer (GC) cell line. Human GC cells (BGC823) were cultured with or without BS-181 at different concentrations for 24-72 hours. BS-181 significantly reduced the activity of CDK7 with downregulation of cyclin D1 and XIAP in GC cells. Treatment with BS-181 induced cell cycle arrest and apoptosis. The expression of Bax and caspase-3 was significantly increased, while Bcl-2 expression was decreased in cells treated with BS-181. In addition, the inhibition of CDK7 with BS-181 resulted in reduced rates of proliferation, migration, and invasion of gastric cells. Those results demonstrated the anticancer activities of selective CDK7 inhibitor BS-181 in BGC823 cells, suggesting that CDK7 may serve as a novel therapeutic target or the treatment of GC.
13
Cyclin D1 is a nuclear protein required for cell cycle progression in G1.
Véronique Baldin, Jiří Lukáš, María Jesús Marcote et al. · Genes & Development · 1993 · 1.6K citations · Full text
Recent patterns in gastric cancer: A global overview
Paola Bertuccio, Liliane Chatenoud, Fabio Levi et al. · International Journal of Cancer · 2009 · 638 citations · Full text